Parkman Healthcare Partners LLC Has $9.78 Million Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Parkman Healthcare Partners LLC trimmed its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 15.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 508,283 shares of the company's stock after selling 92,415 shares during the period. Syndax Pharmaceuticals comprises about 1.2% of Parkman Healthcare Partners LLC's holdings, making the stock its 28th biggest position. Parkman Healthcare Partners LLC owned about 0.60% of Syndax Pharmaceuticals worth $9,784,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of SNDX. BNP PARIBAS ASSET MANAGEMENT Holding S.A. acquired a new stake in shares of Syndax Pharmaceuticals during the 3rd quarter worth about $15,165,000. Eventide Asset Management LLC acquired a new stake in Syndax Pharmaceuticals during the third quarter worth approximately $15,150,000. First Turn Management LLC acquired a new position in Syndax Pharmaceuticals in the 2nd quarter valued at $13,147,000. Sofinnova Investments Inc. lifted its stake in shares of Syndax Pharmaceuticals by 33.9% during the 2nd quarter. Sofinnova Investments Inc. now owns 2,153,669 shares of the company's stock worth $44,215,000 after purchasing an additional 545,129 shares during the period. Finally, Millennium Management LLC grew its position in shares of Syndax Pharmaceuticals by 56.3% in the second quarter. Millennium Management LLC now owns 1,065,508 shares of the company's stock valued at $21,875,000 after purchasing an additional 383,634 shares during the period.

Syndax Pharmaceuticals Stock Performance

Shares of NASDAQ:SNDX traded up $0.30 during trading hours on Wednesday, hitting $16.92. 1,432,015 shares of the company's stock traded hands, compared to its average volume of 1,169,547. The company has a market cap of $1.44 billion, a price-to-earnings ratio of -4.58 and a beta of 0.86. Syndax Pharmaceuticals, Inc. has a 52 week low of $15.00 and a 52 week high of $25.34. The company's fifty day simple moving average is $18.38 and its two-hundred day simple moving average is $19.73.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last announced its earnings results on Tuesday, November 5th. The company reported ($0.98) EPS for the quarter, topping the consensus estimate of ($1.13) by $0.15. The firm had revenue of $12.50 million during the quarter, compared to analyst estimates of $9.16 million. During the same quarter in the previous year, the business earned ($0.73) earnings per share. On average, analysts anticipate that Syndax Pharmaceuticals, Inc. will post -2.39 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

SNDX has been the topic of a number of research reports. Citigroup raised their price objective on Syndax Pharmaceuticals from $37.00 to $45.00 and gave the stock a "buy" rating in a report on Tuesday, November 19th. Stifel Nicolaus raised their price target on shares of Syndax Pharmaceuticals from $40.00 to $41.00 and gave the company a "buy" rating in a report on Monday, October 14th. Bank of America raised their target price on shares of Syndax Pharmaceuticals from $30.00 to $31.00 and gave the company a "buy" rating in a research note on Thursday, August 15th. UBS Group began coverage on shares of Syndax Pharmaceuticals in a research note on Thursday, October 24th. They issued a "buy" rating and a $37.00 target price on the stock. Finally, StockNews.com lowered Syndax Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, November 23rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the company. According to MarketBeat, Syndax Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $37.64.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).